Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2025-09-19 Director's Dealing
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity
Director's Dealing Classification · 100% confidence The document is an official announcement regarding the exercise of stock options by company directors (CEO and CFO) and the subsequent issuance of new equity. It includes a 'Notification of Dealing' form as required by Article 19(1) of the EU Market Abuse Regulation (MAR). While it mentions share issuance, the primary focus is on the directors' transactions and the regulatory disclosure of those dealings. Therefore, it is classified as a Director's Dealing (DIRS).
2025-09-19 English
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
Interim / Quarterly Report Classification · 95% confidence The document is a 'Correction' to a previously published half-year financial results announcement. It explicitly includes the income statement, balance sheet, and cash flow statements for the period of 1 January – 30 June 2025. Because it contains the actual financial statements and substantive financial analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report (IR) rather than a mere announcement. H1 2025
2025-09-12 English
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'Half-Year Financial Results' report for Faron Pharmaceuticals for the period ending 30 June 2025. It contains detailed financial statements (consolidated key figures), management commentary (CEO statement), and operational updates. It is not merely an announcement of a report, as it includes the actual financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-27 English
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) informing investors that the company will publish its half-year financial results on a future date (August 27, 2025). It provides details on the upcoming webcast and contact information. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2025-08-19 English
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA
Legal Proceedings Report Classification · 100% confidence The document is a company announcement from Faron Pharmaceuticals regarding positive feedback from the FDA on a clinical trial development plan. It is labeled as 'Inside Information' and details the advancement of a drug candidate into a Phase 2/3 study. This type of announcement, which provides updates on clinical trial progress and regulatory interactions, is best classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement of material information.
2025-08-18 English
Faron Pharmaceuticals Ltd: Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is the regulatory standard for reporting changes in significant share ownership (major shareholding notifications). It explicitly details the identity of the issuer, the person subject to the notification, and the resulting percentage of voting rights. This fits the definition of a Major Shareholding Notification (MRQ).
2025-08-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.